Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,476 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment E Clear all
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elranatamab, Daratumumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
26
States / cities
Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Mifepristone and Misoprostol for Fetal Demise

NCT00177372
View directory record Official record
Conditions
Anembryonic Pregnancy, Gestation Abnormality, Intrauterine Fetal Demise Term
Interventions
mifepristone/misoprostol
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

NCT05379972
View directory record Official record
Conditions
Gastric Cancer, GastroEsophageal Cancer
Interventions
Pembrolizumab, Olaparib, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Colorado Spring, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Taconic Health Information Network and Community (THINC)

NCT00225563
View directory record Official record
Conditions
Medication Errors
Interventions
Electronic Health Record
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Fishkill, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

STEPS: Substance Use Trial of E-cigarettes or Pharmacotherapy for Smoking

NCT06922617
View directory record Official record
Conditions
Tobacco Use, Substance Use Disorders
Interventions
Switching to E-Cigarette, Quitting using Medication, Counseling
Behavioral · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
4
States / cities
Charleston, South Carolina • Conway, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Terminated Not applicable Interventional

A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion

NCT04586179
View directory record Official record
Conditions
Concussion, Mild, Sport Injury
Interventions
Aerobic (treadmill) Exercise, Dynamic (Agility) Exercise
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 17, 2026, 7:15 PM EDT
Not listed Not applicable Interventional

Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)

NCT01511523
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Disease
Interventions
RGMA001, Sugar Pill
Dietary Supplement
Lead sponsor
Biovil Research Group, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Fayetteville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 17, 2026, 7:15 PM EDT
Active, not recruiting Not applicable Interventional

Technology-Enhanced Palliative Care for Advanced Cancer Patients

NCT04989556
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm
Interventions
Interview, Palliative Therapy, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

NCT00852761
View directory record Official record
Conditions
Plaque-Type Psoriasis
Interventions
Olux-E Foam, Clobex lotion
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2012 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BCG Vaccination Delivered Intradermally, Orally and by Combined Routes

NCT00396370
View directory record Official record
Conditions
Tuberculosis
Interventions
BCG strain Connaught, BCG strain Danish, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 17, 2026, 7:15 PM EDT
Not listed Not applicable Interventional

The Effect of Electronic Cigarette Use on Smoking Behaviors Among Smokers Receiving Outpatient Psychiatric Treatment

NCT04014322
View directory record Official record
Conditions
Tobacco Smoking, Psychiatric Disorders
Interventions
E-cigarette
Other
Lead sponsor
Fordham University
Other
Eligibility
21 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 17, 2026, 7:15 PM EDT
Terminated Phase 1 Interventional

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

NCT03422094
View directory record Official record
Conditions
Glioblastoma
Interventions
NeoVax, Nivolumab, Ipilimumab, Research blood draw, Leukapheresis for research
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 17, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

NCT05297045
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
RGT001-075, Placebo
Drug · Other
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Doral, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability

NCT06646757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
APP, CBT, HELP, PEER
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

NCT07641738
View directory record Official record
Conditions
Microvascular Disease, Retinal Disease
Interventions
XyCAM CRE Imaging
Device
Lead sponsor
Stuart Terry Eye Associates
Other
Eligibility
21 Years to 100 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional

The Effect of Time-Slot Scheduling and Active Choice on Biometric Screening Participation

NCT01305798
View directory record Official record
Conditions
Preventative Health
Interventions
Scheduling and Active Choice for Biometric Participation
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
18 Years and older
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

NCT05249426
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
BI 765063, Ezabenlimab, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

NCT01359644
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
PSI-7977, Daclatasvir, Ribavirin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
17
States / cities
Coronado, California • San Diego, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 17, 2026, 7:15 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

TAK-071 Scopolamine-Induced Cognitive Impairment Study

NCT02918266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting No phase listed Observational

ExoLuminate Study for Early Detection of Pancreatic Cancer

NCT05625529
View directory record Official record
Conditions
Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions
Not listed
Lead sponsor
Biological Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Methods Project 4: Clinical Trial - Amended

NCT03111537
View directory record Official record
Conditions
Tobacco Smoking
Interventions
Cigarettes, E-Cigarette, Nicotine Gum or Lozenge
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Minneapolis, Minnesota • Buffalo, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366
View directory record Official record
Conditions
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-resistant Ovarian Cancer (PROC), Platinum Sensitive Ovarian Cancer (PSOC), Primary Refractory Ovarian Cancer, Uterine Cancer, Cervical Cancer
Interventions
Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin, Itraconazole
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 7:15 PM EDT